Radius Health will host a conference call today, Wednesday,

BOSTON, December 08, 2021 (GLOBE NEWSWIRE) – Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) has announced that it will host a conference call today, Wednesday, December 8, 2021, at 4 p.m. ET to cover the items below:

  • Discuss the initial results of the wearABLE phase 3 trial
  • Review data presented at the San Antonio Breast Cancer Symposium of the EMERALD Phase 3 trial

Conference Call Information:
National telephone number: 1 (866) 323-7965
International phone number: 1 (346) 406-0961
Conference number: 7691981

A replay of the conference call will be available on December 8 at 7 p.m. ET and a live audio broadcast of the conference call will be archived on the company’s website for ninety days. To access the replay, dial (855) 859-2056 or (404) 537-3406 internationally, using the conference ID number 7691981. Live audio webcast of the call is available from the Investors section of the company’s website, https: /ir.radiuspharm.com/events-and-presentations.

About the department

Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, orphan diseases and oncology. Radius flagship product, TYMLOS® (abaloparatide), has been approved by the United States Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes the experimental injection of abaloparatide for potential use in the treatment of men with osteoporosis; an experimental transdermal system of abaloparatide for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, the elacestrant (RAD1901), for potential use in the treatment of hormone receptor positive breast cancer licensed to the Menarini group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential use in multiple endocrine and metabolic orphan diseases, initially targeting Prader-Willi syndrome.

Investor Contact & Press Relations:
Ethan Holdaway
Email: [email protected]
Telephone: (617) 583-2017

Michael P. Boser